Ritulasta 500 mg Injection
  1. Home
  2. Pharma Products
  3. Plasmagen BioSciences Pvt Ltd
  4. Ritulasta 500 mg Injection

Ritulasta 500 mg Injection

Ritulasta 500 mg Injection contains rituximab, a monoclonal antibody used to treat certain blood cancers and immune-related conditions. It targets CD20-positive B cells and is used in conditions including non-Hodgkin lymphoma and chronic lymphocytic leukemia. The medicine is administered by intravenous infusion under the supervision of a qualified healthcare professional.

BUY NOW

Category

Ritulasta 500 mg Injection contains 500 mg of rituximab and is supplied in a 50 mL presentation. Rituximab binds to the CD20 antigen on B cells, helping reduce targeted B-cell populations. It is administered as an intravenous infusion, with the dose and schedule determined by the specific condition and treatment protocol. The product requires refrigerated storage at 2°C to 8°C and should not be frozen.

Technical Specification

Specification Details
Active Ingredient Rituximab 500 mg
Dosage Form Concentrate for Solution for Infusion
Therapeutic Class Anti-CD20 Monoclonal Antibody
Main Indication Non-Hodgkin Lymphoma
Route of Administration Intravenous Infusion
Storage 2°C to 8°C

Product Also Known As

Ritulasta 500 mg Injection, Ritulasta 500 mg Rituximab Injection, Rituximab 500 mg Injection, Rituximab 500 mg Infusion, Rituximab Oncology Injection, Anti-CD20 Monoclonal Antibody

Related products